CCR5 blockers are a promising new class of anti-HIV drugs that act by binding to the CCR5 coreceptor, thereby reducing the number of CD4-CCR5 complexes available for viral binding by HIV and consequently inhibiting the viral entry stage of the infection cycle [1]. Here, CD4 is linked to infection.